In cadrul ICPR 2020 am particpat la un curs de Terapie Psihedelica……. Terapia psihedelica prinde contur ca abordare de sine statatoare in marea familie a psihoterapiei. Desi cu o istorie foarte veche, din anii 1950, utilizarea substantelor psihedelice impreuna cu psihoterapia revine in ultimii 20 de ani in atentia cercetatorilor si practicienilor. De urmarit! :))
Psychedelics for Clinicians 101 & 102
3-Day Online Workshop for Clinicians, 6 – 8 September 2020
ELIZABETH NIELSON; New York University & Fluence
Dr. Elizabeth Nielson is a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders. Dr. Nielson is a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, MDMA-assisted treatment PTSD, and psilocybin-assisted treatment of treatment resistant depression.
INGMAR GORMAN; MAPS & Fluence
Dr. Ingmar Gorman is a psychologist who specializes in assisting populations who have a relationship with psychedelics. He is the site co-principal investigator and therapist on a Phase 3 clinical trial studying MDMA-assisted psychotherapy for post-traumatic stress disorder. After completing his NIH postdoctoral fellowship at New York University, Dr. Gorman stepped down as director of the Psychedelic Education and Continuing Care Program to focus his efforts on Fluence and the training of future therapists.
This workshop will be held online in an interactive live webinar format. Presenters will give live talks, engage in Q&A by chat and open conversation, provide live demonstrations and discussions, invite participation in meditations and other self-reflection exercises, and engage participants in breakout groups and role plays. Two lead trainers and two assisting trainers will be present for additional support.
This 3-day training offered by psychologists Ingmar Gorman and Elizabeth Nielson is designed for clinicians and healthcare providers who want to learn more about current psychedelic research and clinical practice, including how to work with patients who have a history of psychedelic use or have expressed an interest in using psychedelics. This interactive training includes role plays, demonstrations, case examples, and experiential learning opportunities.
Psychedelics 101: Your patients are curious and so are you: What is all this about psychedelics being used for treatment of addiction and trauma? This session gives an overview of psychedelic drugs, their history, and current research with MDMA and Psilocybin-assisted therapy. This program includes an overview of recent and current clinical trials, outcomes, legal status, and what it all means for the future of addiction and trauma treatment.
- Discuss the historical justifications for psychedelic clinical research
- Describe key theoretical approaches to psychedelic-assisted therapy
- Discuss the state of psychedelic clinical research, rescheduling efforts, and how psychedelic-assisted psychotherapy works with clients
- Compare psychedelic integration psychotherapy to integration in peer and shamanic settings
Psychedelics 102: This day introduces clinical skills for psychedelic harm reduction and integration work in the clinical setting. This program focuses on translating research findings into clinical practice including working with patients who are considering using psychedelics, actually using psychedelics, or have used them. Includes discussion of assessment and integration techniques, resources, and legal and ethical issues.
- Assess clients for key “red flags” that indicate someone should seek specialized psychiatric care after a psychedelic experience
- Utilize principles of psychedelic-assisted therapy in a basic/initial assessment of clients who report psychedelic use
- List contraindications and discuss high risk cases of individuals who are contemplating psychedelic use
- Describe the role of the therapist in an individual’s integration psychotherapy process